Výsledky vyhledávání - "B. J. van Zwieten-Boot"

Risk Minimisation Activities to Minimise Drug-Related Risks: An Overview of Current Practice

Autor: F. Moral, M. van Dartel, Sabine M. J. M. Straus, A. K. Mantel-Teeuwisse, S. H. Mülder, Thijs J. Giezen, B. J. van Zwieten-Boot

Publikováno v: Drug Safety. 31:885-960

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9a31c4ffdf83825f09417c89452ca920
https://doi.org/10.2165/00002018-200831100-00068

Zobrazit plný text záznamu

Are women appropriately represented and assessed in clinical trials submitted for marketing authorization? A review of the database of the European Medicines Agency

Autor: M Rietschel, M Müllner, Spiros Vamvakas, B J van Zwieten-Boot

Publikováno v: Int. Journal of Clinical Pharmacology and Therapeutics. 45:477-484

Objective: There is concern that patients included in trials do not represent the true patient population and women in particular may selectively be excluded. We looked at trial data submitted to the European Medicines Agency (EMEA) by drug companies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d1eec7c9cad0b3b0b87671c758ce636
https://doi.org/10.5414/cpp45477

Zobrazit plný text záznamu

[Severe adverse reactions after the use of sulphur hexafluoride (SonoVue) as an ultrasonographic contrast agent]

Autor: M C H, de Groot, B J, van Zwieten-Boot, A C, van Grootheest

Publikováno v: Nederlands tijdschrift voor geneeskunde. 148(38)

European Medicines Agency (EMEA) recently took precautionary measures to limit the use of the ultrasonographic contrast agent sulphur hexafluoride (SonoVue) in patients with cardiac disease. Throughout Europe a number of serious allergic reactions wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5a66f047246c562af921c972c40d744a
https://pubmed.ncbi.nlm.nih.gov/15497786

Zobrazit plný text záznamu

[Clinical evaluation of efficacy and adverse effects in the (European) registration of drugs: what does it mean for the doctor and patient?]

Autor: P P, Koopmans, P A, de Graeff, B J, van Zwieten-Boot, J F, Lekkerkerker, A W, Broekmans

Publikováno v: Nederlands tijdschrift voor geneeskunde. 144(16)

The clinical criteria for admission of new drugs to the European common market have become more stringent in recent years. Increasingly often, the manufacturer is required to demonstrate that the new drug offers a clinically visible and relevant bene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::699b1587d5d7787d56d4f8b195ca9d6b
https://pubmed.ncbi.nlm.nih.gov/10812445

Zobrazit plný text záznamu

Effectiveness of rivastigmine in Alzheimer's disease

Autor: P. Bentham, R. Gray, E. Sellwood, J. Raftery, M. Rosler, C. E Selai, M. R Trimble, M. N Rossor, R. J Harvey, J G Storosum, B J van Zwieten-Boot, A J A Elferink

Publikováno v: BMJ. 319:640-640

Editor—Two recent reports on rivastigmine in Alzheimer’s disease1,2 provide further proof that cholinesterase inhibitors produce modest improvements in cognitive testing and in clinical impression of change. The new claim is of improved functiona

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0dbf13100019fe68085383ecb5cc77ec
https://doi.org/10.1136/bmj.319.7210.640a

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání